Replication of the INSPIRE Trial in Healthcare Claims Data

Exclusion Criteria

• •COPD exacerbation \[-42, 0\] days
• •Asthma, eczema, atopic dermatitis, allergic rhinitis \[-180, 0\] days
• •Known respiratory disorder other than COPD e.g. pulmonary fibrosis or interstitial lung disease (ILD), sarcoidosis, lymphangioleiomyomatosis, primary/pulmonary tuberculosis, cystic fibrosis, pulmonary hypertension/other pulmonary heart disease, lung/pulmonary malignancies, alpha-1 antitrypsin deficiency, pneumoconioses and other lung diseases due to external agents \[all available data, 0\] days
• •Narrow angle glaucoma or prostatic hyperplasia or obstruction of the neck of the bladder \[-180, 0\] days
• •At least one 30-day supply prescription claims for oral alfuzosin, doxazosin, tamsulosin, silodosin, finasteride 5 mg, dutasteride \[-180,0\] days
• •Lung transplant or lung volume reduction surgery (LVRS) \[all available data, 0\] days
• •Daily long term oxygen therapy (LTOT) \[all available data, 0\] days
• •Beta-blockers (except eye drops) \[-180, 0\] days
• •Evidence of alcohol, drug or solvent abuse \[-180, 0\] days
• •Use of salmeterol, tiotropium and fluticasone containing inhaler use \[-180, 0\] days